Drug-Eluting Stents (DES) are coated with one or more medications that are released in the body post-implantation.
The purpose of the medication is to prevent excessive growth of scar tissue in the artery lining.
This enables the artery to remain smooth and patent, ensuring full-fledged blood flow while reducing the chances of artery constriction and restenosis.
It should be considered, however, that using a DES increases the probability of blood clot appearance (stent thrombosis).
As the healing process is relatively slow, patients with implanted drug-eluting stents should strictly follow their physician’s recommendations regarding dual anti-platelet therapy (DAT) to reduce the risk of stent thrombosis.
A minimum therapy mentioned above is recommended for at least 12 months after the implantation of a DES.